☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Eli lilly
Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events
November 19, 2024
Eli Lilly Reports the MHRA’s Approval of Kisunla (Donanemab) to Treat Mild Cognitive Impairment and Mild Dementia Due to Alzheimer...
October 23, 2024
Eli Lilly Highlights 1 Year Analysis from the P-III (VIVID-1) Trial of Mirikizumab for Treating Crohn's Disease at UEG Week 2024
October 15, 2024
PharmaShots' Key Highlights of Third Quarter 2024
October 1, 2024
Eli Lilly's Kisunla (Donanemab-azbt) Receives the MHLW’s Approval for Treating Early Symptomatic Alzheimer's Disease (AD)
September 25, 2024
Eli Lilly’s Ebglyss (L ebrikizumab-lbkz) Receives the US FDA’s Approval for Treating Moderate-to-Severe Atopic Dermatitis
September 16, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.